News Channels

15 May 2017 Glenmark Pharmaceuticals to Initiate Clinical Study for GBR 1342, Second Investigational New Drug from Immuno-Oncology Portfolio
15 May 2017 Otsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125)
15 May 2017 Immunomic Therapeutics Announces Exclusive License of Phase II Cancer Immunotherapy Technology Targeting Cytomegalovirus (CMV)
15 May 2017 Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Patients with Advanced Solid Tumors
15 May 2017 Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac
15 May 2017 Sangamo Therapeutics Presents Recent Developments from Research and Clinical Programs at Annual Meeting of the American Society of Gene & Cell Therapy
15 May 2017 Long-term Data Confirm Benefits of Treatment with Strensiq(R) (asfotase alfa) in Adolescents and Adults with Hypophosphatasia (HPP) Through Five Years
15 May 2017 Formation Biologics Announces Dosing of First Patient in a Phase I/IIa Trial of AVID100, Closing of Series B Financing, and Appointment of Dr. Anthony Tolcher to its Board of Directors
15 May 2017 Biogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric Stroke
15 May 2017 Summit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMD
15 May 2017 Amicus Therapeutics Announces Positive Functional Data from Initial Patients in Pompe Phase 1/2 Study
15 May 2017 MOLOGEN AG: Recruitment goal achieved for the pivotal IMPALA study with lefitolimod in colorectal cancer patients
15 May 2017 Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration
15 May 2017 BioNTech Announces Positive Results of an International Reproducibility Study with MammaTyper®
15 May 2017 Isarna Presents Positive Clinical Data for ISTH0036 in Advanced Glaucoma and Preclinical Data Supportive of AMD/DME Potential at ARVO 2017 Annual Conference
15 May 2017 IMBRUVICA® (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
15 May 2017 Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints
14 May 2017 Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas
14 May 2017 Dendreon Announces Results of New PROCEED Registry Analysis Showing Overall Survival Benefit with PROVENGE® in Men with Metastatic Prostate Cancer
14 May 2017 Intellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual Meeting

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top